{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T03:36:33Z","timestamp":1793763393706,"version":"4.6.1"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2021R1A6A1A03044296"],"award-info":[{"award-number":["2021R1A6A1A03044296"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2026-25520300"],"award-info":[{"award-number":["RS-2026-25520300"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"KHIDI","doi-asserted-by":"publisher","award":["RS-2026-254-959988"],"award-info":[{"award-number":["RS-2026-254-959988"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"name":"MICT","id":[{"id":"https:\/\/ror.org\/05panfw02","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Adaptive designs are increasingly employed to improve trial efficiency; however, their benefits over fixed designs in late-phase oncology trials remain underexplored. We aimed to determine whether adaptive designs in phase 3 cancer trials are associated with primary completion time and primary endpoint success compared with fixed designs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This cross-sectional study analyzed phase 3 randomized lung and breast cancer trials initiated between 2000 and 2020 using Aggregate Analysis of ClinicalTrials.gov database (static version downloaded April 15, 2025). Eligible trials had time-to-event primary endpoints and were completed or terminated. Trials were classified as adaptive or nonadaptive based on preplanned design modifications. Associations between trial design and primary completion time were examined using Kaplan\u2013Meier curves and multivariable cause-specific Cox regression, while associations between trial design and primary endpoint success were examined using multivariable logistic regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 421 eligible trials, 210 employed adaptive designs. Adoption of adaptive designs increased over time, with group-sequential designs being the most common adaptive approach. Adaptive designs showed earlier primary completion, but no statistically significant association was observed after multivariable adjustment. Adaptive trials had higher hazards of early stopping for efficacy or futility and lower hazards of administrative termination. Among 396 trials with available results, 163 achieved primary endpoint success. Adaptive trials had higher odds of success than nonadaptive trials (66.26% vs 33.74%; odds ratio [OR] = 2.363, 95% CI = 1.491 to 3.778; P\u2009&amp;lt;\u2009.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Adaptive designs were associated with higher primary endpoint success but not shorter primary completion time. Given high failure rates in late-phase oncology, adaptive designs may improve efficiency primarily by facilitating data-driven decisions rather than accelerating trial timelines.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jnci\/djag129","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T11:42:06Z","timestamp":1777030926000},"page":"1888-1898","source":"Crossref","is-referenced-by-count":1,"title":["Adaptive design increased success but does not significantly accelerate confirmatory oncology trials"],"prefix":"10.1093","volume":"118","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6507-915X","authenticated-orcid":false,"given":"Sujata","family":"Purja","sequence":"first","affiliation":[{"name":"Data Science, Evidence-Based and Clinical Research Laboratory, Department of Health, Social, and Clinical Pharmacy, College of Pharmacy, Chung-Ang University , Seoul,","place":["Republic of Korea"]},{"name":"Central Research Centre of Epigenome based Platform and Its Application for Drug Development, College of Pharmacy, Chung-Ang University , Seoul,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3525-8805","authenticated-orcid":false,"given":"Eunyoung","family":"Kim","sequence":"additional","affiliation":[{"name":"Data Science, Evidence-Based and Clinical Research Laboratory, Department of Health, Social, and Clinical Pharmacy, College of Pharmacy, Chung-Ang University , Seoul,","place":["Republic of Korea"]},{"name":"Central Research Centre of Epigenome based Platform and Its Application for Drug Development, College of Pharmacy, Chung-Ang University , Seoul,","place":["Republic of Korea"]},{"name":"Chung-Ang University, Department of Pharmaceutical, Biohealth industry Seoul, 06974,","place":["Republic of Korea"]},{"name":"Chung-Ang University, Department of Pharmaceutical Regulatory Science, Seoul, 06974,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"2026100903523213400_djag129-B1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12916-018-1017-7","article-title":"Adaptive designs in clinical trials: why use them, and how to run and report them","volume":"16","author":"Pallmann","year":"2018","journal-title":"BMC Med"},{"key":"2026100903523213400_djag129-B2","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/sim.6472","article-title":"Twenty-five years of confirmatory adaptive designs: opportunities and pitfalls","volume":"35","author":"Bauer","year":"2016","journal-title":"Stat Med"},{"key":"2026100903523213400_djag129-B3","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2307\/2529473","article-title":"Adaptive treatment assignment methods and clinical trials","volume":"33","author":"Simon","year":"1977","journal-title":"Biometrics"},{"key":"2026100903523213400_djag129-B4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/B978-0-12-237301-5.50007-5","volume-title":"Perspectives in Biometrics","author":"Hoel","year":"1975"},{"key":"2026100903523213400_djag129-B5","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2307\/2529944","article-title":"Allocation of patients to treatment in clinical trials","volume":"35","author":"Pocock","year":"1979","journal-title":"Biometrics"},{"key":"2026100903523213400_djag129-B6","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1002\/sim.4780101203","article-title":"A decade of progress in statistical methodology for clinical trials","volume":"10","author":"Simon","year":"1991","journal-title":"Stat Med"},{"key":"2026100903523213400_djag129-B7","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1002\/sim.2626","article-title":"Issues in the use of adaptive clinical trial designs","volume":"25","author":"Emerson","year":"2006","journal-title":"Stat Med"},{"key":"2026100903523213400_djag129-B8","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1186\/s13063-016-1493-z","article-title":"Attitudes and opinions regarding confirmatory adaptive clinical trials: a mixed methods analysis from the Adaptive Designs Accelerating Promising Trials into Treatments (ADAPT-IT) project","volume":"17","author":"Meurer","year":"2016","journal-title":"Trials"},{"key":"2026100903523213400_djag129-B9","author":"European Medicines Agency","year":"2007"},{"key":"2026100903523213400_djag129-B10","author":"U.S. Food and Drug Administration","year":"2019"},{"key":"2026100903523213400_djag129-B11","year":"2025"},{"key":"2026100903523213400_djag129-B12","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with Covid-19","volume":"384","author":"Horby","year":"2021","journal-title":"N Engl J Med"},{"key":"2026100903523213400_djag129-B13","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/s12874-024-02272-9","article-title":"Adaptive designs in clinical trials: a systematic review-Part I","volume":"24","author":"Ben-Eltriki","year":"2024","journal-title":"BMC Med Res Methodol"},{"key":"2026100903523213400_djag129-B14","doi-asserted-by":"crossref","first-page":"202","DOI":"10.12793\/tcp.2023.31.e21","article-title":"Adaptive design clinical trials: current status by disease and trial phase in various perspectives","volume":"31","author":"Lee","year":"2023","journal-title":"Transl Clin Pharmacol"},{"key":"2026100903523213400_djag129-B15","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41392-024-01760-0","article-title":"New clinical trial design in precision medicine: discovery, development and direction","volume":"9","author":"Duan","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"2026100903523213400_djag129-B16","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s12282-024-01601-6","article-title":"Breast cancer epigenetics: current and evolving treatment","volume":"31","author":"Purja","year":"2024","journal-title":"Breast Cancer"},{"key":"2026100903523213400_djag129-B17","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1158\/2159-8274.CD-10-0010","article-title":"The BATTLE trial: personalizing therapy for lung cancer","volume":"1","author":"Kim","year":"2011","journal-title":"Cancer Discov"},{"key":"2026100903523213400_djag129-B18","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1513750","article-title":"Adaptive randomization of neratinib in early breast cancer","volume":"375","author":"Park","year":"2016","journal-title":"N Engl J Med"},{"key":"2026100903523213400_djag129-B19","doi-asserted-by":"crossref","first-page":"e2415445","DOI":"10.1001\/jamanetworkopen.2024.15445","article-title":"Costs of drug development and research and development intensity in the US, 2000-2018","volume":"7","author":"Sertkaya","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026100903523213400_djag129-B20","doi-asserted-by":"crossref","first-page":"100855","DOI":"10.1016\/j.conctc.2021.100855","article-title":"Factors associated with successful phase III trials for solid tumors: a systematic review","volume":"24","author":"Otsuka","year":"2021","journal-title":"Contemp Clin Trials Commun"},{"key":"2026100903523213400_djag129-B21","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/cts.12852","article-title":"Exploratory analysis of the factors associated with success rates of confirmatory randomized controlled trials in cancer drug development","volume":"14","author":"Wu","year":"2021","journal-title":"Clin Transl Sci"},{"key":"2026100903523213400_djag129-B22","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1186\/s12885-021-08457-5","article-title":"Food and drug administration approvals in phase 3 cancer clinical trials","volume":"21","author":"Abi Jaoude","year":"2021","journal-title":"BMC Cancer"},{"key":"2026100903523213400_djag129-B23","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/s41434-023-00437-7","article-title":"Analysis and comparative evaluation of expedited programs for gene therapy products: insights from the United States, the European Union, Japan, and South Korea","volume":"31","author":"Jeong","year":"2024","journal-title":"Gene Ther"},{"key":"2026100903523213400_djag129-B24","doi-asserted-by":"crossref","first-page":"3778","DOI":"10.1200\/JCO-24-01654","article-title":"Oncology accelerated approval confirmatory trials: when a failed trial is not a failed drug","volume":"42","author":"Mehta","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026100903523213400_djag129-B25","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1056\/NEJMra1510061","article-title":"Adaptive designs for clinical trials","volume":"375","author":"Bhatt","year":"2016","journal-title":"N Engl J Med"},{"key":"2026100903523213400_djag129-B26","doi-asserted-by":"crossref","first-page":"e018320","DOI":"10.1136\/bmjopen-2017-018320","article-title":"Adaptive design clinical trials: a review of the literature and ClinicalTrials.gov","volume":"8","author":"Bothwell","year":"2018","journal-title":"BMJ Open"},{"key":"2026100903523213400_djag129-B27","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s12874-023-02024-1","article-title":"A systematic review of randomised controlled trials with adaptive and traditional group sequential designs - applications in cardiovascular clinical trials","volume":"23","author":"Zhang","year":"2023","journal-title":"BMC Med Res Methodol"},{"key":"2026100903523213400_djag129-B28","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s43441-024-00670-1","article-title":"A systematic review of adaptive seamless clinical trials for Late-Phase Oncology Development","volume":"58","author":"Broglio","year":"2024","journal-title":"Ther Innov Regul Sci"},{"key":"2026100903523213400_djag129-B29","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s13063-016-1273-9","article-title":"Adaptive designs undertaken in clinical research: a review of registered clinical trials","volume":"17","author":"Hatfield","year":"2016","journal-title":"Trials"},{"key":"2026100903523213400_djag129-B30","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jclinepi.2022.12.010","article-title":"Reporting quality was suboptimal in a systematic review of randomized controlled trials with adaptive designs","volume":"154","author":"Purja","year":"2023","journal-title":"J Clin Epidemiol"},{"key":"2026100903523213400_djag129-B31","doi-asserted-by":"crossref","first-page":"e0141104","DOI":"10.1371\/journal.pone.0141104","article-title":"An investigation of the shortcomings of the CONSORT 2010 statement for the reporting of group sequential randomised controlled trials: a methodological systematic review","volume":"10","author":"Stevely","year":"2015","journal-title":"PLoS One"},{"key":"2026100903523213400_djag129-B32","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1002\/sim.4156","article-title":"Exploring the benefits of adaptive sequential designs in time-to-event endpoint settings","volume":"30","author":"Emerson","year":"2011","journal-title":"Stat Med"},{"key":"2026100903523213400_djag129-B33","doi-asserted-by":"crossref","first-page":"e2221140","DOI":"10.1001\/jamanetworkopen.2022.21140","article-title":"Economic evaluation of cost and time required for a platform trial vs conventional trials","volume":"5","author":"Park","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2026100903523213400_djag129-B34","doi-asserted-by":"crossref","first-page":"e2014682","DOI":"10.1001\/jamanetworkopen.2020.14682","article-title":"Assessment of trends in the design, accrual, and completion of trials registered in ClinicalTrials.gov by sponsor type, 2000-2019","volume":"3","author":"Gresham","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2026100903523213400_djag129-B35","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"2026100903523213400_djag129-B36","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S1470-2045(23)00182-1","article-title":"Global funding for cancer research between 2016 and 2020: a content analysis of public and philanthropic investments","volume":"24","author":"McIntosh","year":"2023","journal-title":"Lancet Oncol"},{"key":"2026100903523213400_djag129-B37","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1186\/s12891-022-05714-x","article-title":"Characteristics of clinical trials related to hip fractures and factors associated with completion","volume":"23","author":"Wang","year":"2022","journal-title":"BMC Musculoskelet Disord"},{"key":"2026100903523213400_djag129-B38","doi-asserted-by":"crossref","first-page":"636561","DOI":"10.3389\/fonc.2021.636561","article-title":"Value of adaptive trials and surrogate endpoints for clinical decision-making in rare cancers","volume":"11","author":"Krendyukov","year":"2021","journal-title":"Front Oncol"},{"key":"2026100903523213400_djag129-B39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12874-025-02730-y","article-title":"Adaptive designs for trials aiming to optimise implementation strategies and the effect of an additional interim analysis: a simulation study","volume":"26","author":"Nolan","year":"2025","journal-title":"BMC Med Res Methodol"},{"key":"2026100903523213400_djag129-B40","doi-asserted-by":"crossref","first-page":"m115","DOI":"10.1136\/bmj.m115","article-title":"The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design","volume":"369","author":"Dimairo","year":"2020","journal-title":"BMJ"},{"key":"2026100903523213400_djag129-B41","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1750-1172-3-11","article-title":"Adaptive design methods in clinical trials - a review","volume":"3","author":"Chow","year":"2008","journal-title":"Orphanet J Rare Dis"},{"key":"2026100903523213400_djag129-B42","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1750-1172-6-79","article-title":"Benefits, challenges and obstacles of adaptive clinical trial designs","volume":"6","author":"Chow","year":"2011","journal-title":"Orphanet J Rare Dis"},{"key":"2026100903523213400_djag129-B43","author":"U.S. Food and Drug Administration","year":"2018"},{"key":"2026100903523213400_djag129-B44","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1001\/jamaoncol.2025.1002","article-title":"Overall survival and quality-of-life superiority in modern Phase 3 oncology trials: a meta-epidemiological analysis","volume":"11","author":"Sherry","year":"2025","journal-title":"JAMA Oncol"},{"key":"2026100903523213400_djag129-B45","first-page":"Mr000033","article-title":"Industry sponsorship and research outcome","volume":"2","author":"Lundh","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2026100903523213400_djag129-B46","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/annonc\/mdy305","article-title":"Role of industry funders in oncology RCTs published in high-impact journals and its association with trial conclusions and time to publication","volume":"29","author":"Liang","year":"2018","journal-title":"Ann Oncol"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djag129\/68189363\/djag129.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/118\/10\/1888\/68189363\/djag129.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/118\/10\/1888\/68189363\/djag129.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T07:52:46Z","timestamp":1791532366000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article\/118\/10\/1888\/8665119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":46,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,4,29]]},"published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djag129","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,4,29]]}}}